Paper Details

  1. Home
  2. Paper Details

Etanercept to Control Inflammation in the Treatment of Complicated Neurocysticercosis.

Author: CoyleChristina M, MahantySiddhartha, NashTheodore E, WareJeanAnne M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.

Overview

This study evaluated the use of etanercept, a tumor necrosis factor-alpha inhibitor, to control inflammation in patients with neurocysticercosis (NCC). The study found that etanercept administration was associated with clinical improvement, stable disease, absence of recurrence, and lack of serious side effects. Etanercept may offer a promising alternative to corticosteroids in managing NCC-related inflammation.
Paper Details　
Original Abstract of the Article :
Manifestations of neurocysticercosis (NCC) are primarily due to host inflammatory responses directed at drug-damaged or naturally degenerating metacestodes (cysts) of the tapeworm <i>Taenia solium</i>. Prolonged high-dose corticosteroids are frequently required to control this inflammation in compli...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402894/

データ提供：米国国立医学図書館（NLM）

Etanercept: A New Oasis for Neurocysticercosis

This study examines the potential of etanercept, a tumor necrosis factor-alpha inhibitor, for managing inflammation associated with neurocysticercosis (NCC), a parasitic infection of the central nervous system. The researchers reviewed the clinical course of 16 patients with NCC who were treated with etanercept, evaluating its effectiveness in controlling inflammation and facilitating corticosteroid taper. The study provides valuable insights into the potential of etanercept as a novel treatment option for NCC, offering a potential alternative to long-term corticosteroid therapy.

Finding Relief in the Desert of Neurocysticercosis

Imagine a camel struggling with a persistent infection, its body weakened and its journey hampered. Neurocysticercosis (NCC), like a persistent infection, can cause significant inflammation and neurological complications. This study explores the potential of etanercept to manage this challenging condition, offering a new oasis of hope for those seeking relief from the debilitating effects of NCC. The researchers found that etanercept was effective in controlling inflammation and facilitating corticosteroid taper, potentially improving the long-term outcomes for patients with NCC.

The Importance of Multidisciplinary Care

Just as a caravan requires a team of experienced guides to navigate the desert safely, patients with NCC benefit from a multidisciplinary approach to care. This study highlights the need for a collaborative effort between neurologists, infectious disease specialists, and other healthcare professionals to provide comprehensive and individualized care. The findings underscore the importance of ongoing monitoring and treatment adjustments to optimize patient outcomes.

Dr.Camel's Conclusion

This study explores the potential of etanercept as a new treatment option for neurocysticercosis (NCC), offering a potential alternative to long-term corticosteroid therapy. Like a camel finding an oasis in the desert, etanercept offers a glimmer of hope for those seeking relief from the debilitating effects of this infection. The study underscores the importance of multidisciplinary care and ongoing monitoring to optimize patient outcomes.

Date :
  1. Date Completed 2020-01-07
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

30608049

DOI: Digital Object Identifier

PMC6402894

Related Literature

Article Analysis
・Side Effects of praziquantel
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.